• Global vs. US Drug Pricing and Market Access

  • 2024/10/22
  • 再生時間: 54 分
  • ポッドキャスト

Global vs. US Drug Pricing and Market Access

  • サマリー

  • In this episode, we sit down with leading Market Access experts and members of ACCESS Forum to compare and contrast the drug pricing and access systems worldwide and the US. Our discussion delves into the distinct approaches taken by government vs. private markets, examining how regulatory environments, pricing controls, and reimbursement processes impact patient access to innovative therapies. We explore the challenges each approach faces, from cost pressures to affordability and access, and how they balance the interests of patients, governments, and pharmaceutical companies. Join us for a deep dive into how the global healthcare landscape is evolving and what lessons can be learned.

    Nikos Maniadakis, Ph.D., Professor, Health Management & Policy, University of West Attica
    Kimberly Baldwin, Senior Vice President, Value & Access, Ipsen Biopharmaceuticals
    Fauzea Hussain, Vice President, Public Policy, McKesson
    CMS (Centers for Medicare & Medicaid Services)
    European Medicines Agency
    Health technology assessments (HTAs)
    IRA (Inflation Reduction Act)
    Medicaid
    Medicare
    National Institute of Clinical Excellence (NICE)
    NCCN guidelines
    P&T committee (Pharmacy and Therapeutics Committee)
    PAP (Patient Assistance Program)
    Part B (Medicare)
    Part D (Medicare)
    Pharmacy Benefit Managers (PBMs)
    Quality-Adjusted Life Years
    Tricare
    Veterans Administration
    Medical terminology referenced in this episode:

    • Cell and gene therapies (CGT)
    • Insulin
    • Orphan drugs

    Questions or comments?
    Email us at comments@prescriptionforbetteraccess.com.




    続きを読む 一部表示

あらすじ・解説

In this episode, we sit down with leading Market Access experts and members of ACCESS Forum to compare and contrast the drug pricing and access systems worldwide and the US. Our discussion delves into the distinct approaches taken by government vs. private markets, examining how regulatory environments, pricing controls, and reimbursement processes impact patient access to innovative therapies. We explore the challenges each approach faces, from cost pressures to affordability and access, and how they balance the interests of patients, governments, and pharmaceutical companies. Join us for a deep dive into how the global healthcare landscape is evolving and what lessons can be learned.

Nikos Maniadakis, Ph.D., Professor, Health Management & Policy, University of West Attica
Kimberly Baldwin, Senior Vice President, Value & Access, Ipsen Biopharmaceuticals
Fauzea Hussain, Vice President, Public Policy, McKesson
CMS (Centers for Medicare & Medicaid Services)
European Medicines Agency
Health technology assessments (HTAs)
IRA (Inflation Reduction Act)
Medicaid
Medicare
National Institute of Clinical Excellence (NICE)
NCCN guidelines
P&T committee (Pharmacy and Therapeutics Committee)
PAP (Patient Assistance Program)
Part B (Medicare)
Part D (Medicare)
Pharmacy Benefit Managers (PBMs)
Quality-Adjusted Life Years
Tricare
Veterans Administration
Medical terminology referenced in this episode:

  • Cell and gene therapies (CGT)
  • Insulin
  • Orphan drugs

Questions or comments?
Email us at comments@prescriptionforbetteraccess.com.




Global vs. US Drug Pricing and Market Accessに寄せられたリスナーの声

カスタマーレビュー:以下のタブを選択することで、他のサイトのレビューをご覧になれます。